Takeda 2.3 mg Pill - pink capsule/oblong
Generic Name: ixazomib
Pill with imprint Takeda 2.3 mg is Pink, Capsule/Oblong and has been identified as Ninlaro 2.3 mg. It is supplied by Takeda Pharmaceutical Company Limited.
Ninlaro is used in the treatment of Multiple Myeloma and belongs to the drug class proteasome inhibitors. Ninlaro 2.3 mg is not a controlled substance under the Controlled Substances Act (CSA).
Images for Takeda 2.3 mg

Ninlaro
- Generic Name
- ixazomib
- Imprint
- Takeda 2.3 mg
- Strength
- 2.3 mg
- Color
- Pink
- Shape
- Capsule/Oblong
- Availability
- Prescription only
- Drug Class
- Proteasome inhibitors
- CSA Schedule
- Not a controlled drug
- Labeler / Supplier
- Takeda Pharmaceutical Company Limited
- National Drug Code (NDC)
- 63020-0078
- Inactive Ingredients
-
microcrystalline cellulose,
magnesium silicate,
magnesium stearate
Note: Inactive ingredients may vary.
See also:
Abecma
Abecma is a CAR T cell therapy used to treat relapsed refractory multiple myeloma (RRMM); it is a ...
Tecvayli
Tecvayli (teclistamab) is a treatment for relapsed or refractory multiple myeloma. Includes ...
Carvykti
Carvykti (ciltacabtagene autoleucel) is a treatment for relapsed or refractory multiple myeloma ...
Talvey
Talvey is used to treat relapsed or refractory multiple myeloma. Includes Talvey side effects ...
Decadron
Decadron is used for addison's disease, adrenal insufficiency, adrenocortical insufficiency ...
Dexamethasone Intensol
Dexamethasone Intensol is used for addison's disease, adrenal insufficiency, adrenocortical ...
Revlimid
Revlimid is used to treat types of multiple myeloma, mantle cell lymphoma, follicular lymphoma and ...
Adriamycin
Adriamycin is used for acute lymphoblastic leukemia, acute myeloblastic leukemia, bladder cancer ...
Darzalex
Darzalex (daratumumab) is a target therapy used to treat multiple myeloma. Includes DARZALEX uses ...
More about Ninlaro (ixazomib)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (3)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: proteasome inhibitors
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.